Please ensure Javascript is enabled for purposes of website accessibility

How Gilead Sciences Is Driving Forty Seven and Trillium Therapeutics Higher Today

By George Budwell - Feb 28, 2020 at 8:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Gilead is reportedly courting the cancer specialist Forty Seven about a possible buyout.

What happened

Gilead Sciences (GILD 0.83%) is reportedly in buyout, or possible licensing, talks with the clinical-stage cancer company Forty Seven (FTSV), according to Bloomberg. Forty Seven's lead drug candidate, magrolimab, targets a fairly unique therapeutic pathway named CD47. By inhibiting this cell-signaling pathway, magrolimab allows the immune system to better recognize tumor cells, while triggering a potent therapeutic response (phagocytosis by macrophages).

In response to this buyout rumor, Forty Seven's shares jumped by 32.7% in pre-market action Friday morning. Rival drugmaker Trillium Therapeutics Inc. (TRIL) is also getting a nice boost on the heels of this news. Specifically, Trillium's stock is up by a hefty 43% in pre-market trading today.

Two businesspeople shaking hands over a pile of cash and paperwork.

Image source: Getty Images.

Trillium is developing two CD47-based therapies, TTI-621 and TTI-622, for a wide range of blood cancers and disorders. However, Forty Seven's magrolimab is significantly further along in the development process. As a result, the market has awarded Forty Seven a demonstrably higher market cap than rival Trillium (about 10 times higher, to be exact). Investors seem intrigued by this massive valuation gap, given their overwhelmingly positive response to Trillium's stock this morning. 

So what

While no details have been released yet, Gilead can certainly afford to pay top dollar for Forty Seven. The biotech exited the most recent quarter with close to $26 billion in cash and cash equivalents, so this could be a sizable deal. Keeping with this theme, Forty Seven reportedly had multiple buyout offers on the table, a fact that should give the drugmaker an enormous amount of leverage during these ongoing talks. 

On the Trillium side of the equation, investors seem to think that this biotech's tiny market cap might attract a suitor as well. Unfortunately, the reality of the situation is that suitors tend to pursue drugs with a clear first-mover advantage, like magrolimab. So there's no overarching reason to believe that Gilead's interest in Forty Seven will bleed through to Trillium. These two companies sport markedly different value propositions for potential suitors, after all.  

Now what

Within the next few days, the magnitude of Gilead's interest in Forty Seven should become clear. The long and short of it is that Gilead needs to beef up its oncology pipeline. The potential tie-up with Forty Seven would go a long way toward achieving this key operational goal. What's more, Gilead should have plenty of ammunition left over following any deal with Forty Seven. Gilead, in fact, seems destined to pursue a so-called "bolt-on" acquisition in addition to these pipeline-building efforts. 

Should investors buy Forty Seven or Trillium's stocks on this buyout rumor? Forty Seven appears to be the real deal. If Gilead doesn't pull the trigger, someone else likely will. So investors may indeed want to pounce on this mid-cap biotech stock soon.

Trillium's story, on the other hand, is a bit more complicated. The company could turn out to be grossly undervalued if its pipeline hits pay dirt. But it's also a long way from any needle-moving clinical milestones. As such, investors might want to take a wait-and-see approach with this pre-revenue biotech stock for the moment. 

George Budwell has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$61.60 (0.83%) $0.51
Forty Seven, Inc. Stock Quote
Forty Seven, Inc.
Trillium Therapeutics Inc. Stock Quote
Trillium Therapeutics Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.